Trident Texofab approves Q2 FY27 unaudited financial results

Trident Texofab Limited announced that its Board of Directors has approved the Un-Audited Standalone Financial Results for the quarter and half-year ended September 30, 2026. The company also took on record the Limited Review Report issued by the Statutory Auditor. The Board Meeting, held on November 5, 2026, commenced at 07:00 p.m. and concluded at 07:45 p.m..

Trident Texofab Board Approves Financial Results

The Board of Directors of Trident Texofab Limited convened for a meeting on November 5, 2026, during which they approved the Un-Audited Standalone Financial Results for the second quarter and half-year period ended September 30, 2026. The board also formally accepted the Limited Review Report accompanying these financial statements, which was prepared by the company’s Statutory Auditor.

Key Financial Highlights and Review

The Un-Audited Standalone Financial Results, along with the Limited Review Report, have been filed in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These documents are also available on the company’s official website at www.tridenttexofab.com. In addition to the financial results, the Board also took note of various compliances undertaken by the company during the quarter and half-year ending September 30, 2026.

Meeting Details

The Board Meeting commenced promptly at 07:00 p.m. and concluded within an hour, at 07:45 p.m. on November 5, 2026. The company has requested stakeholders to kindly take note of these proceedings and update their records accordingly.

Financial Statement Summary (as at September 30, 2026)

The unaudited financial statements as of September 30, 2026, show total assets amounting to ₹11,738.04 Lakhs, while total equity and liabilities stand at ₹11,738.04 Lakhs. Key figures include Equity Share Capital of ₹1,499.58 Lakhs and Other Equity of ₹4,171.22 Lakhs. Current liabilities include Borrowings of ₹2,466.88 Lakhs.

Quarterly Performance Overview

For the quarter ended September 30, 2026, Trident Texofab reported total income of ₹2,683.38 Lakhs and a profit after tax of ₹60.40 Lakhs. This compares to a total income of ₹2,632.79 Lakhs and a profit after tax of ₹52.18 Lakhs for the same quarter in the previous year (September 30, 2025).

Source: BSE

Previous Article

Welspun Enterprises Limited submits Monitoring Agency Report for Q2 FY27